Business Context and Reporting Period
This Form 8-K Current Report was filed by Phathom Pharmaceuticals, Inc. (PHAT) on April 11, 2025. The report discloses a corporate governance event: the appointment of a new director to the Board of Directors, effective April 16, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or operational metrics.
Material Changes
The material change disclosed is the addition of Theodore R. Schroeder to the Board of Directors as a Class I director. His initial term expires at the 2026 annual meeting of stockholders. Mr. Schroeder will serve on the audit committee.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The document details Mr. Schroeder's extensive background, including over three decades of experience in drug development and commercialization, with prior leadership roles at Nabriva Therapeutics, Zavante Therapeutics, and Cadence Pharmaceuticals. It also notes his previous board service at Cidara Therapeutics, Otonomy, Inc., and Collegium Pharmaceutical.
Compensatory Arrangements: In connection with his appointment, Mr. Schroeder received:
- An option to purchase 35,000 shares of common stock (10-year term, vesting over three years).
- 21,000 restricted stock units (RSUs) vesting over three years.
- Cash compensation in accordance with the Non-Employee Director Compensation Program.
The Board determined that Mr. Schroeder meets the independence requirements of the Nasdaq Stock Market. No related person transactions exist.
Investor Verification Checklist
- Verify the effective date of the director appointment (April 16, 2025) and the expiration of the initial term (2026 annual meeting).
- Confirm the specific vesting schedules for the 35,000 stock options and 21,000 RSUs granted to the new director.
- Review the Company's Non-Employee Director Compensation Program to understand the cash compensation structure.
- Check for any subsequent filings regarding the composition of the Audit Committee following this appointment.